Association between citalopram serum levels and clinical improvement of patients with major depression

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 281-286

  Haji, Elnaz Ostad ^a   Tadić, André ^a   Wagner, Stefanie ^a   Dragicevic, Aleksandra ^a   Müller, Matthias J ^b   Boland, Katja ^c   Rao, Marie Luise ^c   Fric, Miriam ^d   Laux, Gerd ^d   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Clinic for Psychiatry and Psychotherapy   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Inn Salzach Hospital   (Germany)

Author keywords

antidepressant; citalopram; major depressive disorder; serum concentration; therapeutic drug monitoring

Indexed keywords

CITALOPRAM;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HAMILTON SCALE; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 79955597669     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318218f503     Document Type: Article

References (24)

1. Hirschfeld RM, Montgomery SA, Keller MB, et al. Social functioning in depression: a review. J Clin Psychiatry. 2000;61: 268-275. (Pubitemid 30305368)
2. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143:415-426. (Pubitemid 41341413)
3. DGPPN, BÄ K, KBV, et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung, 1. Auflage 2009. DGPPN, Ä ZQ, AWMF, Berlin, Dü sseldorf; 2009.
4. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8:67-104. (Pubitemid 46690921)
5. Reis M, Lundmark J, Benggtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25:183-191. (Pubitemid 36373425)
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40. (Pubitemid 43050100)
7. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265. (Pubitemid 39587052)
8. Pfuhlmann B, Gerlach M, Burger S, et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl. 2007;72:287-296.
9. Müller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36:98-104. (Pubitemid 36791784)
10. Rasmussen BB, BrLsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154. (Pubitemid 30196816)
11. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci. 2008;258(suppl 1):21-27. (Pubitemid 351421448)
12. Bjerkenstedt L, Flyckt L, OverL FK, et al. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol. 1985;28: 553-557. (Pubitemid 15030781)
13. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835. (Pubitemid 38625335)
14. Grasmäder K, Lohmann PL, Kuss HJ, et al. Therapeutisches drug-monitoring von AntidepressivaVtherapeutischer und gesundheitö konomischer Nutzen. Med Mo Pharm. 2003;26:162-164. (Pubitemid 36596829)
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
16. Müller MJ, Dragicevic A. Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. J Affect Disord. 2003;77:65-69. (Pubitemid 37205152)
17. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334:1-100. (Pubitemid 17115352)
18. Frahnert C, Rao ML, Grasmäder K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;794:35-47. (Pubitemid 36897624)
19. Greiner C, Hiemke C, Bader W, et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl (es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:391-394. (Pubitemid 46453308)
20. Reis M, Olsson G, Carlsson B, et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol. 2002;22: 406-413. (Pubitemid 34810331)
21. de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J. 2010. [Epub ahead of print].
22. Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand. 2000;101:354-359. (Pubitemid 30233000)
23. Mann K, Hiemke C, Schmidt LG, et al. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit. 2006;28:83-85.
24. Mann K, Hiemke C, Lotz J, et al. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol. 2006;26:671-673. (Pubitemid 44772752)